Project Grant R01AI187603
Award Date
6/6/25
Completion Date
5/31/30
Dollars Obligated
$617K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award of $2,366,783.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to determine the molecular processes by which infectious spores of the fungus Cryptococcus transition into vegetatively growing yeast (germinate) and how this process influences disease. The overarching goal is to gain a better understanding of the fundamental biology of pathogenic fungi,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,797,623 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to decipher the significance of pathogen genetic variation and evolution. The 5-year research project, which commenced on July 8, 2024, will use a combination of genetics and experimental evolution to understand complex epistasis with respect to genetic...
This $2,917,725 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel antifungal agents for treating coccidioidomycosis, a severe fungal infection caused by Coccidioides spp. The key research objectives are to: 1) perform structure-activity relationship (SAR) studies on a lead antifungal candidate compound to optimize its activity; 2) investigate the...
This $443,944.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by the University of Georgia Research Foundation to study the genetic basis of two key pathogenesis traits in the fungal genus Cryptococcus - thermotolerance and azole drug resistance. The research aims to employ high-throughput genetic approaches to characterize how genome-wide factors...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $749,594 to study the role of the host sphingosine kinase 1 (SK1) pathway in controlling Cryptococcus neoformans infection during immunodeficiency. The awardee, The Research Foundation For The State University Of New York (Stony Brook University), will use a mouse model to investigate how the...
This federal Project Grant award for $158,433, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the metabolic mechanisms that allow the pathogenic fungus Cryptococcus neoformans to tolerate high levels of carbon dioxide as a virulence trait. The research will define the metabolic profile induced by carbon dioxide stress across diverse Cryptococcus isolates, and examine how...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research at Prokaryotics Incorporated to develop novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The $170,000 award, running from February 1, 2025 to January 31, 2027, supports structural elucidation of the C. albicans GPI ethanolamine phosphate transferase enzyme...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the discovery and development of new antifungal therapeutics. The goal is to identify inhibitors of the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth across different environmental conditions. By targeting CER1, the project aims to develop a more potent antifungal...
This federal Project Grant award, totaling $494,696.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate translational control mechanisms that enable the fungal pathogen Candida albicans to respond to host environmental stresses and transition between yeast and filamentous...